Restricted by the health care system and the medical inspection level (Chinese
firms mainly lag behind foreign counterparts in molecular diagnostics and
other special tests), Chinese independent clinical laboratory market only
values RMB2.5-3 billion, equivalent to 2%-3% of the total revenue of medical
diagnosis, much lower than 30% in developed countries.
However, in the context of Chinese medical reform, the cost control of public
hospitals, the increasing number of patients that primary medical institutions
are confronted with, the rapid development of private hospitals and other
factors will greatly boost China independent clinical laboratory industry
which will grow at a rate over 40%.
The report focuses on the operation, advantages and characteristics of 10
major independent clinical laboratory companies in China on the basis of an
analysis on the development environment, the market situation, the competition
pattern, the impact of upstream and downstream as well as the prospect of
China independent clinical laboratory industry.
In China, among about 110 laboratories engaged in independent medical
diagnosis, top four ones, namely Kingmed Diagnostics, ADICON, DiAn Diagnostics
and DaAn Health, master more than 70% domestic market share together, all with
the chain integrated diagnostic service mode.
As a giant in China independent clinical laboratory industry, Kingmed
Diagnostics has maintained a revenue growth rate of more than 50% in the past
five years. It achieved the revenue of over RMB1 billion in 2012 with 21
laboratories, over 13,000 clients (including more than 1,000 Grade-A
hospitals) and 1,600 types of inspection services. Moreover, the company has
received two rounds of capital injection from Lenovo, and always stood at the
leading position of the industry.
ADICON and DiAn Diagnostics are located in the second echelon in the industry.
ADICON targets at the high-end field (including 220 special inspection items),
with 15 laboratories, only second to Kingmed Diagnostics. In June 2012, the
subsidiary Hefei ADICON became a designated cervical and breast cancer
diagnosis institution in Hefei by virtue of the strong and efficient
diagnostic service network.
China's first listed independent clinical laboratory enterprise DiAn
Diagnostics gained the revenue of RMB414 million from independent medical
diagnostic services in 2012, up 52.2% year on year. DiAn Diagnostics shows
significant unique competitive advantages, reflected in hierarchical
management and "agency + services" business model. As of the end of 2012, DiAn
Diagnostics owned 13 independent diagnostic laboratories, and planned to
establish 15 Class-A laboratories and 30 Class-B ones by 2016 for the purpose
of the overall improvement in the service response speed.